US FDA’s relatively slow path to market may cost small manufacturers more than $40m more than they’d spend in countries with easier device approvals, device-center head Jeffrey Shuren acknowledged at the Food & Drug Law Institute’s Annual Conference May 4 in Washington, DC.
The figure, which was compiled by Versant Ventures, includes $1.8m for eight extra weeks waiting to meet with FDA; $5.5m...





